Title: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
Abstract: Arthritis & RheumatismVolume 33, Issue 3 p. 305-315 ArticleFree to Read Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis William P. Arend MD, Corresponding Author William P. Arend MD Professor and Head, Rheumatology Division, University of Colorado School of Medicine Division of Rheumatology, Department of Medicine, University of Colorado Health Sciences Center, Denver, and the Division of Immunology and Allergy, Hǒpital Cantonal Universitaire, Geneva, Switzerland.Division of Rheumatology, Box B 115, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262Search for more papers by this authorJean-Michel Dayer MD, Jean-Michel Dayer MD Associate Professor, Hǒpital Cantonal Universitaire Division of Rheumatology, Department of Medicine, University of Colorado Health Sciences Center, Denver, and the Division of Immunology and Allergy, Hǒpital Cantonal Universitaire, Geneva, Switzerland.Search for more papers by this author William P. Arend MD, Corresponding Author William P. Arend MD Professor and Head, Rheumatology Division, University of Colorado School of Medicine Division of Rheumatology, Department of Medicine, University of Colorado Health Sciences Center, Denver, and the Division of Immunology and Allergy, Hǒpital Cantonal Universitaire, Geneva, Switzerland.Division of Rheumatology, Box B 115, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262Search for more papers by this authorJean-Michel Dayer MD, Jean-Michel Dayer MD Associate Professor, Hǒpital Cantonal Universitaire Division of Rheumatology, Department of Medicine, University of Colorado Health Sciences Center, Denver, and the Division of Immunology and Allergy, Hǒpital Cantonal Universitaire, Geneva, Switzerland.Search for more papers by this author First published: March 1990 https://doi.org/10.1002/art.1780330302Citations: 727AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1. Dayer J-M, Demczuk S: Cytokines and other mediators in rheumatoid arthritis. Springer Semin Immunopathol 7: 387–413, 1984 2. Zvaifler NJ: New perspectives on the pathogenesis of rheumatoid arthritis. Am J Med 85A: 12–17, 1988 3. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M: Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet II: 244–247 1989 4. Alvaro-Gracia JM, Zvaifler NJ, Firestein GS: Cytokines in chronic inflammatory arthritis. IV. Granulocyte/ macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med 170: 865–875, 1989 5. Dinarello CA: Interleukin-1 and its biologically related cytokines. Adv Immunol 44: 153–205, 1989 6. Miossec P: The role of interleukin 1 in the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 5: 305–308, 1987 7. Dayer J-M, De Rochemonteix B, Burrus B, Demczuk S, Dinarello CA: Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest 77: 645–648, 1986 8. Evěquoz V, Bettens F, Kristensen F, Trechsel U, Stadler BM, Dayer J-M, De Weck AL, Fleisch H: Interleukin 2-independent stimulation of rabbit chondrocyte collagenase and prostaglandin E2 production by an interleukin 1-like factor. Eur J Immunol 14: 490–495, 1984 9. Postlethwaite AE, Raghow R, Stricklin GP, Poppleton H, Seyer JM, Kang AH: Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1α and β. J Cell Biol 106: 311–318, 1988 10. Raines EW, Dower SK, Ross R: Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 243: 393–396, 1989 11. Krane SM, Dayer J-M, Simon LE, Byrne MS: Mononuclear cell-conditioned medium containing mononuclear cell factor (MCF), homologous with interleukin 1, stimulates collagen and fibronectin synthesis by adherent rheumatoid synovial cells: effects of prostaglandin E2 and indomethacin. Coll Relat Res 5: 99–117, 1985 12. Yaron I, Meyer FA, Dayer J-M, Bleiberg I, Yaron M: Some recombinant human cytokines stimulate glycosaminoglycan synthesis in human synovial fibroblast cultures and inhibit it in human articular cartilage cultures. Arthritis Rheum 32: 173–180, 1989 13. Goldring MB, Birkhead J, Sandell LJ, Kimura T, Krane SM: Interleukin 1 suppresses expression of cartilagespecific types II and IX collagens and increases type I and III collagens in human chondrocytes. J Clin Invest 82: 2026–2037, 1988 14. Dayer J-M, Trentham DE, Krane SM: Collagens act as ligands to stimulate human monocytes to produce mononuclear cell factor (MCF) and prostaglandins (PGE2). Coll Relat Res 2: 523–540, 1982 15. Dayer J-M, Ricard-Blum S, Kaufmann M-T, Herbage D: Type IX collagen is a potent inducer of PGE2 and interleukin 1 production by human monocyte macrophages. FEBS Lett 198: 208–212, 1986 16. Arner EC, Pratta MA: Independent effects of interleukin-1 on proteoglycan breakdown, proteoglycan synthesis, and prostaglandin E2 release from cartilage in organ culture. Arthritis Rheum 32: 288–297, 1989 17. Pettipher ER, Higgs GA, Henderson B: Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 83: 8749–8753, 1986 18. Stimpson SA, Dalldorf FG, Otterness IG, Schwab JH: Exacerbation of arthritis by IL-1 in rat joints previously injured by peptidoglycan-polysaccharide. J Immunol 140: 2964–2969, 1988 19. Hom JT, Bendele AM, Carlson DG: In vivo administration with IL-1 accelerates the development of collageninduced arthritis in mice. J Immunol 141: 834–841, 1988 20. Jacobs C, Young D, Tyler S, Callis G, Gillis S, Conlon PJ: In vivo treatment with IL-1 reduces the severity and duration of antigen-induced arthritis in rats. J Immunol 141: 2967–2974, 1988 21. Wallach D, Holtmann H, Engelmann H, Nophar Y: Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol 140: 2994–2999, 1988 22. Henderson B, Rowe FM, Bird CR, Gearing AJH: Production of interleukin 1 in the joint during the development of antigen-induced arthritis in the rabbit. Clin Exp Immunol 74: 371–376, 1988 23. Hopkins SJ, Humphreys M, Jayson MIV: Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1. Clin Exp Immunol 72: 422–427, 1988 24. Yamagata N, Kobayashi K, Kasama T, Fukushima T, Tabata M, Yoneya I, Shikama Y, Kaga S, Hashimoto M, Yoshida K, Sekine F, Negishi M, Ide H, Mori Y, Takahashi T: Multiple cytokine activities and loss of interleukin 2 inhibitor in synovial fluids of patients with rheumatoid arthritis. J Rheumatol 15: 1623–1627, 1988 25. Bhardwaj N, Lau LL, Rivelis M, Steinman RM: Interleukin-1 production by mononuclear cells from rheumatoid synovial effusions. Cell Immunol 114: 405–423, 1988 26. Miyasaka N, Sato K, Goto M, Sasano M, Natsuyama M, Inoue K, Nishioka K: Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients: possible involvement in joint destruction. Arthritis Rheum 31: 480–486, 1988 27. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M: Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 73: 449–455, 1988 28. Firestein GS, Alvaro-Gracia JM, Zvaifler NJ: Quantitative analysis of cytokine gene expression in rheumatoid arthritis (abstract). Clin Res 37: 586A, 1989 29. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, Di Giovine FS, Duff GW: Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet II: 706–709, 1988 30. Shore A, Jaglal S, Keystone EC: Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis. Clin Exp Immunol 65: 293–302, 1986 31. Dayer J-M, Seckinger P: Natural inhibitors and antagonists of interleukin 1, Interleukin 1, Inflammation and Disease. Edited by RHR. Bomford, B. Henderson. Amsterdam, Elsevier, 1989 32. Arend WP, Joslin FG, Thompson RC, Hannum CH: An interleukin 1 inhibitor from human monocytes: production and characterization of biological properties. J Immunol 143: 1851–1858, 1989 33. Larrick JW: Native interleukin 1 inhibitors. Immunol Today 10: 61–66, 1989 34. Arend WP, Joslin FG, Massoni RJ: Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. J Immunol 134: 3868–3875, 1985 35. Balavoine J-F, De Rochemonteix B, Williamson K, Seckinger P, Cruchaud A, Dayer J-M: Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest 78: 1120–1124, 1986 36. Seckinger P, Williamson K, Balavoine J-F, Mach B, Mazzei G, Shaw A, Dayer J-M: A urine inhibitor of interleukin 1 activity affects both interleukin 1α and 1β but not tumor necrosis factor α. J Immunol 139: 1541–1545, 1987 37. Seckinger P, Lowenthal JW, Williamson K, Dayer J-M, MacDonald HR: A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol 139: 1546–1549, 1987 38. Roux-Lombard P, Modoux C, Dayer J-M: Production of interleukin 1 (IL-1) and a specific IL-1 inhibitor during human monocyte-macrophage differentiation: influence of GM-CSF. Cytokine 1: 45–51, 1989 39. Lotz M, Carson DA: Transforming growth factor β and cellular immune responses in synovial fluids (abstract). Arthritis Rheum 32 (suppl 4): S42, 1989 40. Lotz M, Tsoukas CD, Robinson CA, Dinarello CA, Carson DA, Vaughan JH: Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies. J Clin Invest 78: 713–721, 1986 41. Roux-Lombard P, Modoux C, Dayer J-M: Inhibitors of IL-1 and TNFα activities in synovial fluids and cultured synovial fluid cell supernatants (abstract). Calcif Tissue Int 42: S(A47), 1988 42. Prieur A-M, Kaufmann M-T, Griscelli C, Dayer J-M: Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 11: 1240–1242, 1987 43. Sherry B, Cerami A: Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J Cell Biol 107: 1269–1277, 1988 44. Dayer J-M, Beutler B, Cerami A: Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162: 2163–2168, 1985 45. Henderson B, Pettipher ER: Arthritogenic actions of recombinant IL-1 and tumour necrosis factor α in the rabbit: evidence for synergistic interactions between eytokines in vivo. Clin Exp Immunol 75: 306–310, 1989 46. Yocum DE, Esparza L, Dubry S, Benjamin JB, Volz R, Scuderi P: Characteristics of tumor necrosis factor production in rheumatoid arthritis. Cell Immunol 122: 131–145, 1989 47. Hopkins SJ, Meager A: Cytokines in synovial fluid. II. The presence of tumour necrosis factor and interferon. Clin Exp Immunol 73: 88–92, 1988 48. Saxne T, Palladino MA Jr, Heinegàrd D, Talal N, Wollheim FA: Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31: 1041–1045, 1988 49. Husby G, Williams RC Jr: Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1: 363–371, 1988 50. Seckinger P, Isaaz S, Dayer J-M: A human inhibitor of tumor necrosis factor α. J Exp Med 167: 1511–1516, 1988 51. Seckinger P, Isaaz S, Dayer J-M: Purification and biologic characterization of a specific tumor necrosis factor α inhibitor. J Biol Chem 264: 11966–11973, 1989 52. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D: A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264: 11974–11980, 1989 53. Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A, Adolf G: Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 42: 270–275, 1989 54. Novick D, Engelmann H, Wallach D, Rubenstein M: Soluble cytokine receptors are present in normal urine. J Exp Med 170: 1409–1414, 1989 55. Wong GG, Clark SC: Multiple actions of interleukin 6 within a cytokine network. Immunol Today 9: 137–139, 1988 56. Guerne P-A, Zuraw BL, Vaughan JH, Carson DA, Lotz M: Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis. J Clin Invest 83: 585–592, 1989 57. Houssiau FA, Devogelaer J-P, Van Damme J, Nagant de Deuxchaisnes C, Van Snick J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31: 784–788, 1988 58. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maini R, Feldmann M, Kishimoto T: Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 18: 1797–1801, 1988 59. Bhardwaj N, Santhanam U, Lau LL, Tatter SB, Ghrayeb J, Rivelis M, Steinman RM, Sehgal PB, May LT: IL-6/IFN-β2 in synovial effusions of patients with rheumatoid arthritis and other arthritides: identification of several isoforms and studies of cellular sources. J Immunol 143: 2153–2159, 1989 60. Miyasaka N, Sato K, Hashimoto J, Kohsaka H, Yamamoto K, Goto M, Inoue K, Matsuda T, Hirano T, Kishimoto T, Nishioka K: Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium. Clin Immunol Immunopathol 52: 238–247, 1989 61. Burmester GR, Jahn B, Rohwer P, Zacher J, Winchester RJ, Kalden JR: Differential expression of Ia antigens by rheumatoid synovial lining cells. J Clin Invest 80: 595–604, 1987 62. Firestein GS, Zvaifler NJ: Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis. II. Low levels of synovial fluid and synovial tissue interferon suggest that γ-interferon is not the primary macrophage activating factor. Arthritis Rheum 30: 864–871, 1987 63. Firestein GS, Xu W-D, Townsend K, Broide D, Alvaro-Gracia J, Glasebrook A, Zvaifler NJ: Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 168: 1573–1586, 1988 64. Xu W-D, Firestein GS, Taetle R, Kaushansky K, Zvaifler NJ: Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 83: 876–882, 1989 65. Williamson DJ, Begley CG, Vadas MA, Metcalf D: The detection and initial characterization of colonystimulating factors in synovial fluid. Clin Exp Immunol 72: 67–73, 1988 66. Hamerman D, Taylor S, Kirschenbaum I, Klagsbrun M, Raines EW, Ross R, Thomas KA: Growth factors with heparin binding affinity in human synovial fluid. Proc Soc Exp Biol Med 186: 384–389, 1987 67. Lafyatis R, Thompson N, Remmers E, Flanders K, Roberts A, Sporn M, Wilder RL: Demonstration of local production of PDGF and TGF-β by synovial tissue from patients with rheumatoid arthritis (abstract). Arthritis Rheum 31 (suppl 4): S62, 1988 68. Butler DM, Leizer T, Hamilton JA: Stimulation of human synovial fibroblast DNA synthesis by plateletderived growth factor and fibroblast growth factor. J Immunol 142: 3098–3103, 1989 69. Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL: Anchorage-independent growth of synoviocytes from arthritic and normal joints: stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 83: 1267–1276, 1989 70. Kumkumian GK, Lafyatis R, Remmers EF, Case JP, Kim S-J, Wilder RL: Platelet-derived growth factor and IL-1 interactions in rheumatoid arthritis: regulation of synoviocyte proliferation, prostaglandin production, and collagenase transcription. J Immunol 143: 833–837, 1989 71. Sporn MB, Roberts AB, Wakefield LM, De Crombrugghe B: Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 105: 1039–1045, 1987 72. Czarniecki CW, Chiu HH, Wong GHW, McCabe SM, Palladino MA: Transforming growth factor-β modulates the expression of class II histocompatibility antigens on human cells. J Immunol 140: 4217–4223, 1988 73. Fava R, Olsen N, Keski-Oja J, Moses H, Pincus T: Active and latent forms of transforming growth factor β activity in synovial effusions. J Exp Med 169: 291–296, 1989 74. Lafyatis R, Thompson NL, Remmers EF, Flanders KC, Roche NS, Kim S-J, Case JP, Sporn MB, Roberts AB, Wilder RL: Transforming growth factor-β production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats: studies on secretion by synovial fibroblast-like cells and immunohistologic localization. J Immunol 143: 1142–1148, 1989 75. Wahl SM, Hunt DA, Bansal G, McCartney-Francis N, Ellingsworth L, Allen JB: Bacterial cell wall-induced immunosuppression: role of transforming growth factor β. J Exp Med 168: 1403–1417, 1988 Citing Literature Volume33, Issue3March 1990Pages 305-315 ReferencesRelatedInformation
Publication Year: 1990
Publication Date: 1990-03-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 957
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot